eledon-logo-1230.png
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
May 01, 2023 07:00 ET | Eledon Pharmaceuticals, Inc.
$35 million in upfront financing with the potential to receive additional aggregate financing up to $105 million, subject to achieving clinical development milestones, plus up to $45 million upon...
eledon-logo-1230.png
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
March 31, 2023 06:00 ET | Eledon Pharmaceuticals, Inc.
Results from three participants demonstrated no incidence of acute rejection at durations of 56, 154, and 232 days Strong graft function observed in all three participants with mean eGFRs above 70...
eledon-logo-1230.png
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
March 30, 2023 16:01 ET | Eledon Pharmaceuticals, Inc.
`Four patients enrolled in open-label Phase 1b kidney transplant trial with clinical data on first three patients to be presented at the World Congress of Nephrology (WCN) on March 31, 2023 Safety...
North American Kidney Transplant Market
North America Kidney Transplant Market Research Report 2023: Calcineurin Inhibitors Revenue will Grow Due to Advancement and Technology in the Healthcare Industry
March 27, 2023 08:58 ET | Research and Markets
Dublin, March 27, 2023 (GLOBE NEWSWIRE) -- The "North America Kidney Transplant Market, Size, Forecast 2023-2027, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company...
eledon-logo-1230.png
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
March 23, 2023 16:05 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it plans to release financial results for the fourth quarter and full...
eledon-logo-1230.png
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
March 23, 2023 08:00 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company will present two posters at the upcoming International...
American Kidney Fund
American Kidney Fund Brings Kidney Health Education to All During Fourth Annual Virtual Kidney Action Week on March 20-24
March 20, 2023 09:23 ET | American Kidney Fund
ROCKVILLE, Md., March 20, 2023 (GLOBE NEWSWIRE) -- Today marks the beginning of the American Kidney Fund’s (AKF) fourth annual Kidney Action Week, a free, week-long virtual event dedicated to...
American Kidney Fund
American Kidney Fund Announces 2023 Class of Corporate Members Supporting the Fight Against Kidney Disease
March 07, 2023 09:54 ET | American Kidney Fund
ROCKVILLE, Md., March 07, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced its 2023 Class of Corporate Members, strategic partners in its Corporate Membership Program....
Global Renal Biomarkers Market
Global Renal Biomarkers Technologies and Market Analysis Report 2022: There is a Gap for an Ideal Renal Biomarker - Market Revenues 2019-2021, Estimates for 2022, and CAGR Projections through 2027
March 02, 2023 05:58 ET | Research and Markets
Dublin, March 02, 2023 (GLOBE NEWSWIRE) -- The "Renal Biomarkers: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The report examines recent...
Kidney Month: A Time
Kidney Month: A Time of Unity and Action on Behalf of 37 Million Living with Kidney Disease
February 28, 2023 09:33 ET | American Kidney Fund
ROCKVILLE, Md., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Tomorrow, the American Kidney Fund (AKF) will kick off the first day of Kidney Month, which raises awareness of kidney disease, a life-altering...